COMPARATIVE PHARMACOKINETICS OF LOVASTATIN, SIMVASTATIN AND PRAVASTATIN IN HUMANS

被引：102

作者：

PENTIKAINEN, PJ

SARAHEIMO, M

SCHWARTZ, JI

AMIN, RD

SCHWARTZ, MS

BRUNNERFERBER, F

ROGERS, JD

机构：

[1] MERCK SHARP & DOHME LTD,DEPT CLIN PHARMACOL,POB 200,WBD 320,RAHWAY,NJ 07065

[2] MERCK SHARP & DOHME LTD,DEPT DRUG METAB,RAHWAY,NJ 07065

[3] UNIV HELSINKI,DEPT MED 3,SF-00100 HELSINKI 10,FINLAND

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 1992年 / 32卷 / 02期

关键词：

D O I：

10.1002/j.1552-4604.1992.tb03818.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Twelve healthy male volunteers received single market-image 40-mg oral doses of lovastatin and simvastatin (both lactone prodrugs), or pravastatin (alpha beta-hydroxyacid) at 1 week intervals in a three-way crossover study to quantify HMG-CoA reductase inhibitors in plasma. Multiple plasma samples were collected up to 24 hours after the dose and assayed for active and total HMG-CoA reductase inhibitors. After equal oral doses, higher plasma concentrations of HMG-CoA reductase inhibitory activity after pravastatin than after either lovastatin of simvastatin (2-3 fold greater area under the concentration-time curve) suggest a greater potential availability of pravastatin-related inhibitory activity to peripheral tissues.

引用

页码：136 / 140

页数：5

共 19 条

[1] MEVINOLIN - A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME-A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT [J].

ALBERTS, AW ;

CHEN, J ;

KURON, G ;

HUNT, V ;

HUFF, J ;

HOFFMAN, C ;

ROTHROCK, J ;

LOPEZ, M ;

JOSHUA, H ;

HARRIS, E ;

PATCHETT, A ;

MONAGHAN, R ;

CURRIE, S ;

STAPLEY, E ;

ALBERSSCHONBERG, G ;

HENSENS, O ;

HIRSHFIELD, J ;

HOOGSTEEN, K ;

LIESCH, J ;

SPRINGER, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (07) :3957-3961

[2] EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].

BRADFORD, RH ;

SHEAR, CL ;

CHREMOS, AN ;

DUJOVNE, C ;

DOWNTON, M ;

FRANKLIN, FA ;

GOULD, AL ;

HESNEY, M ;

HIGGINS, J ;

HURLEY, DP ;

LANGENDORFER, A ;

NASH, DT ;

POOL, JL ;

SCHNAPER, H .

ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49

[3]

DUGGAN DE, 1989, DRUG METAB DISPOS, V17, P166

[4] TISSUE SELECTIVITY OF THE CHOLESTEROL-LOWERING AGENTS LOVASTATIN, SIMVASTATIN AND PRAVASTATIN IN RATS INVIVO [J].

GERMERSHAUSEN, JI ;

HUNT, VM ;

BOSTEDOR, RG ;

BAILEY, PJ ;

KARKAS, JD ;

ALBERTS, AW .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 158 (03) :667-675

[5]

GERSON RJ, 1989, AM J MED, V87

[6] TISSUE-SELECTIVE INHIBITION OF CHOLESTEROL-SYNTHESIS INVIVO BY PRAVASTATIN SODIUM, A 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE INHIBITOR [J].

KOGA, T ;

SHIMADA, Y ;

KURODA, M ;

TSUJITA, Y ;

HASEGAWA, K ;

YAMAZAKI, M .

BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1045 (02) :115-120

[7] EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .2. ASSESSMENT OF THE HUMAN LENS AFTER 48 WEEKS OF TREATMENT WITH LOVASTATIN [J].

LATIES, AM ;

SHEAR, CL ;

LIPPA, EA ;

GOULD, AL ;

TAYLOR, HR ;

HURLEY, DP ;

STEPHENSON, WP ;

KEATES, EU ;

TUPYVISICH, MA ;

CHREMOS, AN .

AMERICAN JOURNAL OF CARDIOLOGY, 1991, 67 (06) :447-453

[8] PRECLINICAL EVALUATION OF LOVASTATIN [J].

MACDONALD, JS ;

GERSON, RJ ;

KORNBRUST, DJ ;

KLOSS, MW ;

PRAHALADA, S ;

BERRY, PH ;

ALBERTS, AW ;

BOKELMAN, DL .

AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (15) :J16-J27

[9]

MOSLEY ST, 1989, J LIPID RES, V30, P1411

[10] COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF PRAVASTATIN AND LOVASTATIN [J].

PAN, HY ;

DEVAULT, AR ;

WANGIVERSON, D ;

IVASHKIV, E ;

SWANSON, BN ;

SUGERMAN, AA .

JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (12) :1128-1135

← 1 2 →